On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. November 20, 2020-- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. Rockville's Immunomic Therapeutics Inc. is on track to go public later this year, after Covid-19 threw a wrench in the vaccine maker's initial timeline. Stock ticker symbol (e.g. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . Our goal is to overcome the limitations of current immuno-oncology therapies by . Amy Conrad The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. In addition, ITI-1001 represents a far more cost-effective approach. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). 301-968-3501 Bard (Becton, Dickinson and Company). Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that have the . Companies. ITI maintains its headquarters in Rockville, Maryland. ITI Media: We provide a professional and challenging work environment . Melissa Kemp Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. 28 Employees . ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics may be just for you. mcarey@rxir.com Nature. Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Prior to joining ITI, Ms. Harrison worked as a consultant for various biotechnology companies focused on oncology and infectious disease, leading client interactions with global regulatory authorities regarding product approvals and regulatory planning and implementation. The Immunomic Therapeutics, Inc. team includes specialists in the areas of science, process development, engineering, production, marketing, finance, human resources, quality and regulatory, administrative support and more. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Coordinates: 245831.9N 1213154.0E. 2016;2016:4857869. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. ITI Company: We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. Immunomic Therapeutics, Inc. Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company revolutionizing the study of the Lysosomal Associated Membrane . This represents the second closing in the investment process for the HLB Consortium, ($10M was placed in February 2020), and substantially increases their holding in Immunomic Therapeutics to 47.6% of the common stock. Immunomic Therapeutics investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Active, Closed, Last funding round type (e.g. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time mkemp@immunomix.com At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. Founders Sungwuk Kim. This is the Immunomic Therapeutics company profile. Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. 717-327-1822, ITI Media: ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. Rockville, Maryland, 20850, United States. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Phone Number +4989208047700. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. For more information, please visit www.immunomix.com. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. The company is developing three small molecule products; its lead development program, IMU-838, a selective . Background. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . HLB also secured an option to make further investment into the company in the months ahead. Share this article. Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). What is health insurance like at Immunomic Therapeutics. As a result, we make a significant investment in our employees through our Compensation, Health and Wellness, Retirement and Disability and Career Development programs. You will receive a reply to confirm the receipt of your application. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Juniper Point GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. 2017 Aug;47:85-92. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. Today, Brian Stamper, VP, Immunomic Therapeutics, will participate at #MTC's Annapolis Day 2023. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics, Inc. may be just for you. Phone Number +119196161923. April 23, 2020 04:00 PM Eastern Daylight Time. For consideration, please send your company information, a copy of your standard search agreement, and references to: careers@immunomix.com. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. You can also compare prices and book all best hotels in New Taipei City with one-stop booking service on Trip.com. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. 858-366-3243, Internet Explorer presents a security risk. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. 917-322-2571, Internet Explorer presents a security risk. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. mcarey@rxir.com Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates. To explore Immunic Therapeutics's full profile, request access. ITI maintains its headquarters in Rockville, Maryland. Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. mkemp@immunomix.com ITI Company: Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. For more information, please visit www.immunomix.com. ITI-2000 provides an UNITE platform address for HPV+ cancers. Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. 2017 Apr 15;23(8):1898-1909. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. Since the Astellas deals, we have nearly doubled our research team to include deeper oncology expertise, including vaccinology, even neoantigen vaccine specialization. Batich, K.A., Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. To demonstrate our dedication to patients and our understanding of the importance of clinical trials, we have created a . We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Handled COVID very well. January 30, 2015 - Immunomic Therapeutics, Inc. ("Immunomic Therapeutics "), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to . Request a free trial. 301-968-3501 You are here: hackberry allergy symptoms; 49ers paying players under the table; immunomic therapeutics crunchbase . The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Our company has the capability to successfully plan, design and conduct clinical studies that enable us to establish POC in humans in a timely manner with the underlying capabilities to manufacture clinical trial supplies. SaaS, Android, Cloud Computing, Medical Device). Headquarters Location. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. Last Funding Type Venture - Series Unknown. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. Operating Status Active. Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. Immunic Therapeutics Investments & Acquisitions (2) Company Name Deal Date Deal Type Deal Size Industry Lead Partner; 00000 0000000: 12-Apr-2019: 0000000000: Drug Discovery: 000000 00: 4SC (immunology portfolio) 28-Sep-2016: